New York, January 5, 2026, 14:35 ET — Regular session
- Johnson & Johnson shares fell about 2.2% in afternoon trading, lagging a broader market rise.
- Investors rotated out of defensive healthcare as Wall Street’s risk appetite improved.
- Next catalysts include the Jan. 9 U.S. jobs report and J&J’s Jan. 21 earnings call.
Johnson & Johnson (JNJ) stock fell about 2.2% on Monday as investors trimmed defensive healthcare names. Shares were down $4.49 at $202.86 in afternoon trading after touching a session low of $200.94, with about 4.8 million shares traded.
The timing matters because early-year positioning has shifted quickly toward cyclicals, leaving traditionally steady names with less of a bid. When money flows out of defensives, big healthcare stocks can slide even without a single headline.
Investors are also recalibrating around legal and earnings catalysts that can reprice a stock in a day. For Johnson & Johnson, the talc litigation calendar and the next results cycle sit near the top of that list.
Reuters on Monday flagged the company’s talc docket as a mass-tort fight to watch in 2026, saying lawsuits tying its baby powder to ovarian cancer are expected to ramp up after three unsuccessful attempts to resolve the litigation through bankruptcy. Ovarian cancer claims make up the bulk of more than 67,000 remaining cases, and a special master — a court-appointed adviser — is expected in the coming weeks to revisit expert evidence in federal proceedings in New Jersey, the report said. J&J has said its products are safe, do not contain asbestos and do not cause cancer.
At 11:48 a.m. ET, the Dow was up 1.46% and the S&P 500 added 0.85%, with the Dow hitting an all-time high as energy shares climbed after a U.S. military strike captured Venezuelan President Nicolas Maduro, Reuters reported. “It’s normal for markets to try to start a new month or a new year on a positive tone,” said Steve Sosnick, chief market analyst at Interactive Brokers, as defensive pockets of the market lagged. Reuters
The next macro catalyst is Friday’s U.S. Employment Situation report for December, due at 8:30 a.m. ET on Jan. 9. The release can swing Treasury yields and rate expectations, which often bleeds into how investors price dividend-paying defensive stocks.
Beyond the macro backdrop, investors are positioning ahead of J&J’s quarterly update for any shift in its 2026 outlook and any change in litigation-related reserves. Legal provisions can move reported profit even if underlying demand for medicines and devices holds steady.
But the legal docket remains hard to handicap. An unfavorable ruling on expert evidence or another run of large verdicts could raise the perceived settlement bill and keep pressure on the shares, regardless of earnings.
Johnson & Johnson is scheduled to host its fourth-quarter 2025 earnings call on Jan. 21 at 8:30 a.m. ET, the next fixed point for investors looking for clearer guidance on both operations and the path of the talc cases.
Related articles: NYSE:JNJ
